Clinical Trials

Pancreatic Neoplasms, Cholangiocarcinoma

NCT07621497 2026-06-02

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

229 enrolled

Colorectal Neoplasms

NCT07603375 2026-05-29

TNT Esophagus

60 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07062536 2026-05-28

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

130 enrolled

Biliary Cancer Metastatic

NCT07606599 2026-05-26

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

398 enrolled

Biliary Tract Neoplasms

NCT07582315 2026-05-22

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

538 enrolled

Biliary Tract Neoplasms

NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Phase 1/2 Not yet recruiting

240 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

12 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07381309 2026-04-28

VVSHIP

114 enrolled

CRC

NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

180 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Biliary Tract Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT07418866 2026-02-18

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07391566 2026-02-06

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

99 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

36 enrolled

Phase 4 Not yet recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms

NCT07325214 2026-01-12

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

136 enrolled

Pancreatic Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

HER2-positive Gastric Cancer

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

138 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

820 enrolled

Stomach Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

129 enrolled

Appendiceal Neoplasms, Colorectal Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Pancreatic Neoplasms

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

737 enrolled

Esophageal Squamous Cell Carcinoma

NCT06783491 2025-11-24

FOXHIPECT4

1,083 enrolled

Colorectal Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07118800 2025-08-12

NACRE-2

160 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

33 enrolled

Phase 1 Not yet recruiting

Stomach Neoplasms

NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

22 enrolled

Advanced Small Intestine Cancer

NCT07028424 2025-07-01

PANORAMIX

206 enrolled